Myriad Genetics, Inc.

Contributing Author

Recent Articles by Myriad Genetics, Inc.

Mar-02	Myriad Commercially Launches Precise MRD with Select Community Oncologists MYGN +8.68% MYGN +5.59% GlobeNewswire
Feb-24	Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests MYGN GlobeNewswire
Feb-23	Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution MYGN GlobeNewswire
Feb-19	FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test MYGN GlobeNewswire
Feb-16	Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 MYGN GlobeNewswire
Jan-27	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data MYGN GlobeNewswire
Jan-12	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance MYGN GlobeNewswire
Jan-05	Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference MYGN +6.19% MYGN GlobeNewswire
Dec-09	Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium MYGN GlobeNewswire
Nov-25	Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health MYGN GlobeNewswire
Nov-11	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences MYGN GlobeNewswire
Nov-10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk Hereditary Cancer Test to Support Evolving Clinical Needs MYGN GlobeNewswire
Nov-06	Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference MYGN GlobeNewswire
Nov-03	Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution MYGN -21.03% MYGN GlobeNewswire
Oct-31	New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner MYGN GlobeNewswire
Oct-27	Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 MYGN GlobeNewswire
Oct-14	Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel MYGN GlobeNewswire
Sep-23	Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy MYGN GlobeNewswire
Sep-04	Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology MYGN GlobeNewswire
Sep-03	New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression MYGN GlobeNewswire
Aug-27	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences MYGN GlobeNewswire
Aug-18	Myriad Genetics Appoints Ben Wheeler Chief Financial Officer MYGN GlobeNewswire
Aug-13	New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results MYGN GlobeNewswire
Aug-05	Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum MYGN +46.51% MYGN GlobeNewswire
Jul-31	Myriad Genetics Announces New $200 Million Credit Facility MYGN -5.19% GlobeNewswire
Jul-29	Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 MYGN -6.39% GlobeNewswire
Jul-15	Myriad Genetics Earns 2025 Great Place To Work Certification MYGN GlobeNewswire
Jun-03	Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen MYGN +9.42% GlobeNewswire
Jun-02	Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types MYGN +6.44% GlobeNewswire
May-27	Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting MYGN +6.14% GlobeNewswire
May-14	Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences MYGN +7.03% MYGN -6.57% GlobeNewswire
May-07	Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology MYGN -41.27% MYGN -5.62% GlobeNewswire
May-06	Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance MYGN -5.58% GlobeNewswire

Myriad Genetics, Inc.

Recent Articles by Myriad Genetics, Inc.

Upgrade your FINVIZ experience